Literature DB >> 1699802

A soluble form of the interleukin-1 receptor produced by a human B cell line.

J A Symons1, G W Duff.   

Abstract

A soluble protein that binds specifically to interleukin-1 (IL-1)beta was released from a B cell line (Raji). The covalently cross-linked binding protein/[125I]IL-1 beta migrated at 60 kDa by SDS-PAGE. The IL-1 receptor (IL-1R) on Raji cells had the same ligand specificity. Stimulation of Raji with dexamethasone increased surface expression of the IL-1R and the rate of release of soluble binding protein. A serine protease inhibitor prevented release of the binding protein and increased IL-1R expression on the cells. These results suggest that the soluble IL-1 beta binding protein is a proteolytically cleaved form of the novel B cell IL-1R.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1699802     DOI： 10.1016/0014-5793(90)80466-v

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  16 in total

Review 1.  The extracellular regulation of growth factor action.

Authors:  R Flaumenhaft; D B Rifkin
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

2.  High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries.

Authors:  S D Yanofsky; D N Baldwin; J H Butler; F R Holden; J W Jacobs; P Balasubramanian; J P Chinn; S E Cwirla; E Peters-Bhatt; E A Whitehorn; E H Tate; A Akeson; T L Bowlin; W J Dower; R W Barrett
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.

Authors:  O Ludwiczek; E Vannier; I Borggraefe; A Kaser; B Siegmund; C A Dinarello; H Tilg
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

4.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.

Authors:  J A Symons; P R Young; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 5.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

6.  The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

Authors:  D Burger; R Chicheportiche; J G Giri; J M Dayer
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  Interleukin 1 signaling occurs exclusively via the type I receptor.

Authors:  J E Sims; M A Gayle; J L Slack; M R Alderson; T A Bird; J G Giri; F Colotta; F Re; A Mantovani; K Shanebeck
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Determination of soluble CD21 as a parameter of B cell activation.

Authors:  H P Huemer; C Larcher; W M Prodinger; A L Petzer; M Mitterer; N Falser
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor alpha subunit.

Authors:  J Tavernier; T Tuypens; G Plaetinck; A Verhee; W Fiers; R Devos
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

Review 10.  The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins.

Authors:  P A Barker; R A Murphy
Journal:  Mol Cell Biochem       Date:  1992-03-04       Impact factor: 3.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.